<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font3" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font6" size="10" family="Times" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="10" family="Times,BoldItalic" color="#000000"/>
<text top="42" left="279" width="54" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">FRASER et al.<i>et al.</i></text>
<text top="754" left="534" width="20" height="11" font="font2" id="p1_t2" reading_order_no="118" segment_no="3" tag_type="text">103<b>103</b></text>
<text top="765" left="227" width="161" height="9" font="font3" id="p1_t3" reading_order_no="117" segment_no="20" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="84" left="55" width="239" height="9" font="font6" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">the 11 patients randomized to alemtuzumab consoli-<i>URRENT</i></text>
<text top="95" left="55" width="239" height="9" font="font6" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">dation; that results compares with a 24.7-month mean<i> O</i></text>
<text top="105" left="55" width="239" height="9" font="font6" id="p1_t6" reading_order_no="3" segment_no="1" tag_type="text">PFS in the 10 patients randomized to observation (p =<i>NCOLOGY</i></text>
<text top="115" left="55" width="239" height="11" font="font6" id="p1_t7" reading_order_no="4" segment_no="1" tag_type="text">0.036). O’Brien et al. 23 reported a median TTP of more<i>—</i></text>
<text top="128" left="55" width="239" height="9" font="font6" id="p1_t8" reading_order_no="5" segment_no="1" tag_type="text">than 24 months in patients who demonstrated a re-<i>V</i></text>
<text top="138" left="55" width="173" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="1" tag_type="text">sponse to alemtuzumab consolidation.<i>OLUME</i></text>
<text top="155" left="55" width="239" height="9" font="font3" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="text">Survival:  Survival data associated with the use of<i> 14, N</i></text>
<text top="166" left="55" width="239" height="9" font="font6" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="text">alemtuzumab consolidation therapy were reported in<i>UMBER</i></text>
<text top="176" left="55" width="239" height="10" font="font6" id="p1_t12" reading_order_no="9" segment_no="4" tag_type="text">the RCT published by the German CLL Study Group 20 .<i> 3</i></text>
<text top="188" left="55" width="239" height="9" font="font6" id="p1_t13" reading_order_no="10" segment_no="4" tag_type="text">Median OS had not been reached in either the</text>
<text top="199" left="55" width="239" height="9" font="font6" id="p1_t14" reading_order_no="11" segment_no="4" tag_type="text">alemtuzumab arm or the observation arm. No other</text>
<text top="210" left="55" width="138" height="9" font="font6" id="p1_t15" reading_order_no="12" segment_no="4" tag_type="text">studies reported survival data.</text>
<text top="232" left="55" width="70" height="9" font="font8" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="title">4.2.2 Question 2<i>p</i> =</text>
<text top="243" left="55" width="239" height="9" font="font3" id="p1_t17" reading_order_no="14" segment_no="7" tag_type="text">What toxicities are associated with the use of<i>et al.</i></text>
<text top="254" left="55" width="67" height="9" font="font3" id="p1_t18" reading_order_no="15" segment_no="7" tag_type="text">alemtuzumab?</text>
<text top="265" left="73" width="221" height="9" font="font6" id="p1_t19" reading_order_no="16" segment_no="8" tag_type="text">Toxicities associated with the administration of</text>
<text top="276" left="55" width="239" height="9" font="font6" id="p1_t20" reading_order_no="17" segment_no="8" tag_type="text">alemtuzumab were reported in most studies (Table IV ).</text>
<text top="287" left="55" width="239" height="9" font="font6" id="p1_t21" reading_order_no="18" segment_no="8" tag_type="text">The most common adverse events can be broadly</text>
<text top="298" left="55" width="138" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="8" tag_type="text">grouped into these categories:</text>
<text top="320" left="55" width="4" height="9" font="font6" id="p1_t23" reading_order_no="20" segment_no="10" tag_type="list">•</text>
<text top="320" left="73" width="128" height="9" font="font6" id="p1_t24" reading_order_no="21" segment_no="10" tag_type="list">Infusion-related side effects<i>Survival:  </i>Survival data associated with the use of</text>
<text top="331" left="55" width="4" height="9" font="font6" id="p1_t25" reading_order_no="22" segment_no="11" tag_type="list">•</text>
<text top="331" left="73" width="85" height="9" font="font6" id="p1_t26" reading_order_no="23" segment_no="11" tag_type="list">Myelosuppression</text>
<text top="342" left="55" width="4" height="9" font="font6" id="p1_t27" reading_order_no="24" segment_no="12" tag_type="list">•</text>
<text top="342" left="73" width="122" height="9" font="font6" id="p1_t28" reading_order_no="25" segment_no="12" tag_type="list">Infection-related toxicities</text>
<text top="364" left="55" width="239" height="9" font="font8" id="p1_t29" reading_order_no="26" segment_no="13" tag_type="text">Infusion-related side effects: Infusion-related side</text>
<text top="374" left="55" width="239" height="10" font="font6" id="p1_t30" reading_order_no="27" segment_no="13" tag_type="text">effects were reported in sixteen studies 5–7,9,11,12,14–</text>
<text top="385" left="55" width="239" height="10" font="font6" id="p1_t31" reading_order_no="28" segment_no="13" tag_type="text">20,22–24 . They occurred in most patients treated with</text>
<text top="397" left="55" width="239" height="9" font="font6" id="p1_t32" reading_order_no="29" segment_no="13" tag_type="text">intravenous alemtuzumab, were usually grade 1 or 2</text>
<text top="408" left="55" width="239" height="9" font="font6" id="p1_t33" reading_order_no="30" segment_no="13" tag_type="text">in severity, and were manageable with appropriate</text>
<text top="419" left="55" width="239" height="9" font="font6" id="p1_t34" reading_order_no="31" segment_no="13" tag_type="text">supportive care. The prophylactic use of pre-medi-</text>
<text top="430" left="55" width="239" height="9" font="font6" id="p1_t35" reading_order_no="32" segment_no="13" tag_type="text">cations was reported in about one third of the studies</text>
<text top="441" left="55" width="239" height="9" font="font6" id="p1_t36" reading_order_no="33" segment_no="13" tag_type="text">and usually consisted of orally administered acetami-<i><b>4.2.2 Question 2</b></i></text>
<text top="452" left="55" width="239" height="9" font="font6" id="p1_t37" reading_order_no="34" segment_no="13" tag_type="text">nophen and antihistamines; corticosteroids were gen-<i>What toxicities are associated with the use of</i></text>
<text top="463" left="55" width="239" height="9" font="font6" id="p1_t38" reading_order_no="35" segment_no="13" tag_type="text">erally reserved for more severe reactions. Grade 3<i>alemtuzumab?</i></text>
<text top="474" left="55" width="239" height="9" font="font6" id="p1_t39" reading_order_no="36" segment_no="13" tag_type="text">or 4 fever, rigour, and nausea were reported in up to</text>
<text top="485" left="55" width="239" height="9" font="font6" id="p1_t40" reading_order_no="37" segment_no="13" tag_type="text">20% of patients; other serious infusion-related tox-</text>
<text top="496" left="55" width="239" height="9" font="font6" id="p1_t41" reading_order_no="38" segment_no="13" tag_type="text">icities were less common. The incidence of infusion-</text>
<text top="507" left="55" width="239" height="9" font="font6" id="p1_t42" reading_order_no="39" segment_no="13" tag_type="text">related side effects was similar regardless of the</text>
<text top="518" left="55" width="239" height="9" font="font6" id="p1_t43" reading_order_no="40" segment_no="13" tag_type="text">population evaluated, tended to be higher and more</text>
<text top="529" left="55" width="239" height="9" font="font6" id="p1_t44" reading_order_no="41" segment_no="13" tag_type="text">severe with the first infusion, and improved with sub-</text>
<text top="540" left="55" width="134" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="13" tag_type="text">sequent courses of treatment.</text>
<text top="551" left="73" width="221" height="9" font="font6" id="p1_t46" reading_order_no="43" segment_no="16" tag_type="text">The subcutaneous administration of alemtuzumab</text>
<text top="561" left="55" width="239" height="10" font="font6" id="p1_t47" reading_order_no="44" segment_no="16" tag_type="text">was reported in three trials 10,15,21 , and this route was</text>
<text top="573" left="55" width="239" height="9" font="font6" id="p1_t48" reading_order_no="45" segment_no="16" tag_type="text">generally much better tolerated than the intravenous</text>
<text top="584" left="55" width="239" height="9" font="font6" id="p1_t49" reading_order_no="46" segment_no="16" tag_type="text">route used in similar patients (Table IV ). Grade 1 or 2</text>
<text top="595" left="55" width="239" height="9" font="font6" id="p1_t50" reading_order_no="47" segment_no="16" tag_type="text">fever (68%) and local injection site reactions (88%)</text>
<text top="606" left="55" width="239" height="9" font="font6" id="p1_t51" reading_order_no="48" segment_no="16" tag_type="text">were reported; grade 3 or 4 reactions of any kind were<i><b>Infusion-related side effects: </b></i>Infusion-related side</text>
<text top="616" left="55" width="210" height="10" font="font6" id="p1_t52" reading_order_no="49" segment_no="16" tag_type="text">rarely reported (fewer than 2% of patients) 15 .</text>
<text top="633" left="55" width="239" height="9" font="font8" id="p1_t53" reading_order_no="50" segment_no="18" tag_type="text">Myelosuppression:  Data regarding myelosuppression</text>
<text top="645" left="55" width="239" height="9" font="font6" id="p1_t54" reading_order_no="51" segment_no="18" tag_type="text">associated with the use of alemtuzumab were reported</text>
<text top="654" left="55" width="239" height="11" font="font6" id="p1_t55" reading_order_no="52" segment_no="18" tag_type="text">in 10 trials 6,7,9–12,15,18–20 . Results for studies evaluating</text>
<text top="666" left="55" width="236" height="9" font="font6" id="p1_t56" reading_order_no="53" segment_no="18" tag_type="text">various disease populations were analyzed separately.</text>
<text top="678" left="73" width="221" height="9" font="font6" id="p1_t57" reading_order_no="54" segment_no="19" tag_type="text">Grades 3 and 4 myelosuppression were common</text>
<text top="689" left="55" width="239" height="9" font="font6" id="p1_t58" reading_order_no="55" segment_no="19" tag_type="text">in studies evaluating alemtuzumab monotherapy for</text>
<text top="698" left="55" width="239" height="10" font="font6" id="p1_t59" reading_order_no="56" segment_no="19" tag_type="text">patients with relapsed or refractory disease 6,7,9–12 . The</text>
<text top="711" left="55" width="239" height="9" font="font6" id="p1_t60" reading_order_no="57" segment_no="19" tag_type="text">pooled estimates for grades 3 and 4 neutropenia,</text>
<text top="722" left="55" width="239" height="9" font="font6" id="p1_t61" reading_order_no="58" segment_no="19" tag_type="text">thrombocytopenia, and anemia were 39% (range:</text>
<text top="84" left="318" width="239" height="9" font="font6" id="p1_t62" reading_order_no="59" segment_no="2" tag_type="text">22%–66%), 31% (range: 23%–46%), and 8% (range:</text>
<text top="95" left="318" width="239" height="9" font="font6" id="p1_t63" reading_order_no="60" segment_no="2" tag_type="text">0%–28%) respectively. Similar rates of grades 3 and 4</text>
<text top="105" left="318" width="239" height="9" font="font6" id="p1_t64" reading_order_no="61" segment_no="2" tag_type="text">myelosuppression were reported for studies evaluat-</text>
<text top="117" left="318" width="239" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="2" tag_type="text">ing alemtuzumab in combination and in maintenance</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t66" reading_order_no="63" segment_no="2" tag_type="text">or consolidation regimens. Data regarding the co-</text>
<text top="138" left="318" width="239" height="9" font="font6" id="p1_t67" reading_order_no="64" segment_no="2" tag_type="text">administration of hematopoietic growth factors were</text>
<text top="150" left="318" width="82" height="9" font="font6" id="p1_t68" reading_order_no="65" segment_no="2" tag_type="text">not well reported.</text>
<text top="166" left="318" width="239" height="9" font="font8" id="p1_t69" reading_order_no="66" segment_no="5" tag_type="text">Infection-Related Toxicity: Data regarding the inci-</text>
<text top="177" left="318" width="239" height="9" font="font6" id="p1_t70" reading_order_no="67" segment_no="5" tag_type="text">dence of infections in patients treated with alem-</text>
<text top="187" left="318" width="239" height="10" font="font6" id="p1_t71" reading_order_no="68" segment_no="5" tag_type="text">tuzumab were reported in twenty publications 5–20,22,23,</text>
<text top="198" left="318" width="239" height="10" font="font6" id="p1_t72" reading_order_no="69" segment_no="5" tag_type="text">25,28 . In thirteen studies, antimicrobial prophylaxis was</text>
<text top="210" left="318" width="239" height="9" font="font6" id="p1_t73" reading_order_no="70" segment_no="5" tag_type="text">administered during alemtuzumab therapy. The most</text>
<text top="221" left="318" width="239" height="9" font="font6" id="p1_t74" reading_order_no="71" segment_no="5" tag_type="text">frequently cited combination was cotrimoxazole to-</text>
<text top="232" left="318" width="239" height="9" font="font6" id="p1_t75" reading_order_no="72" segment_no="5" tag_type="text">gether with antiviral therapy (acyclovir, valacyclovir,</text>
<text top="243" left="318" width="239" height="9" font="font6" id="p1_t76" reading_order_no="73" segment_no="5" tag_type="text">famciclovir) for the prevention of Pneumocystis</text>
<text top="254" left="318" width="239" height="9" font="font3" id="p1_t77" reading_order_no="74" segment_no="5" tag_type="text">carinii pneumonia ( PCP ) and herpes virus infections.</text>
<text top="265" left="318" width="239" height="9" font="font6" id="p1_t78" reading_order_no="75" segment_no="5" tag_type="text">For the present systematic review, data relating to</text>
<text top="276" left="318" width="239" height="9" font="font6" id="p1_t79" reading_order_no="76" segment_no="5" tag_type="text">infection-related toxicity were analyzed and reported</text>
<text top="287" left="318" width="187" height="9" font="font6" id="p1_t80" reading_order_no="77" segment_no="5" tag_type="text">separately for various study populations.</text>
<text top="303" left="318" width="239" height="9" font="font3" id="p1_t81" reading_order_no="78" segment_no="9" tag_type="text">Single-Agent Alemtuzumab for Relapsed or Refrac-</text>
<text top="315" left="318" width="238" height="9" font="font3" id="p1_t82" reading_order_no="79" segment_no="9" tag_type="text">tory CLL : Data pertaining to infection-related morbid-</text>
<text top="326" left="318" width="239" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="9" tag_type="text">ity in patients with relapsed or refractory CLL were<i><b>Myelosuppression:  </b></i>Data regarding myelosuppression</text>
<text top="335" left="318" width="239" height="10" font="font6" id="p1_t84" reading_order_no="81" segment_no="9" tag_type="text">reported in eight studies 5–12 . The per capita incidence</text>
<text top="348" left="318" width="239" height="9" font="font6" id="p1_t85" reading_order_no="82" segment_no="9" tag_type="text">of all infections ranged from 30 to 93 per 100 pa-</text>
<text top="359" left="318" width="239" height="9" font="font6" id="p1_t86" reading_order_no="83" segment_no="9" tag_type="text">tients (46 per 100 patients across studies). The inci-</text>
<text top="369" left="318" width="239" height="9" font="font6" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">dence of grades 3 and 4 infections ranged from 7 to</text>
<text top="381" left="318" width="239" height="9" font="font6" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">36 per 100 patients (18 per 100 across studies), and</text>
<text top="392" left="318" width="239" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">infection-related mortality ranged from 0 to 10 per</text>
<text top="402" left="318" width="189" height="9" font="font6" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">100 patients (4.5 per 100 across studies).</text>
<text top="414" left="336" width="221" height="9" font="font6" id="p1_t91" reading_order_no="88" segment_no="14" tag_type="text">Grades 3 and 4 infections included disseminated</text>
<text top="425" left="318" width="239" height="9" font="font6" id="p1_t92" reading_order_no="89" segment_no="14" tag_type="text">viral infections [for example, varicella–zoster virus</text>
<text top="435" left="318" width="239" height="9" font="font6" id="p1_t93" reading_order_no="90" segment_no="14" tag_type="text">and herpes simplex virus ( HSV )], systemic Candida</text>
<text top="447" left="318" width="239" height="9" font="font6" id="p1_t94" reading_order_no="91" segment_no="14" tag_type="text">infections, mycobacterial reactivation, and invasive</text>
<text top="458" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="92" segment_no="14" tag_type="text">fungal infections (for example, pulmonary aspergillo-</text>
<text top="468" left="318" width="239" height="9" font="font6" id="p1_t96" reading_order_no="93" segment_no="14" tag_type="text">sis, rhinocerebral mucormycosis, and cryptococcal</text>
<text top="480" left="318" width="239" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="14" tag_type="text">meningitis and pneumonia). Infection with PCP was</text>
<text top="491" left="318" width="239" height="9" font="font6" id="p1_t98" reading_order_no="95" segment_no="14" tag_type="text">reported, but these cases generally occurred in pa-</text>
<text top="501" left="318" width="149" height="9" font="font6" id="p1_t99" reading_order_no="96" segment_no="14" tag_type="text">tients not receiving prophylaxis.</text>
<text top="513" left="336" width="221" height="9" font="font6" id="p1_t100" reading_order_no="97" segment_no="15" tag_type="text">The incidence of CMV reactivation was reported</text>
<text top="522" left="318" width="239" height="11" font="font6" id="p1_t101" reading_order_no="98" segment_no="15" tag_type="text">in seven of the above-mentioned trials 5,6,8–11,13 and</text>
<text top="534" left="318" width="238" height="9" font="font6" id="p1_t102" reading_order_no="99" segment_no="15" tag_type="text">ranged from 1% to 29% (9% across studies); CMV</text>
<text top="546" left="318" width="239" height="9" font="font6" id="p1_t103" reading_order_no="100" segment_no="15" tag_type="text">pneumonitis was reported in 4 patients (0.8% across<i><b>Infection-Related Toxicity: </b></i>Data regarding the inci-</text>
<text top="557" left="318" width="239" height="9" font="font6" id="p1_t104" reading_order_no="101" segment_no="15" tag_type="text">studies). The actual risk of CMV reactivation in this</text>
<text top="567" left="318" width="239" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="15" tag_type="text">patient population was not clear because most stud-</text>
<text top="579" left="318" width="201" height="9" font="font6" id="p1_t106" reading_order_no="103" segment_no="15" tag_type="text">ies did not prospectively screen all patients.</text>
<text top="588" left="336" width="220" height="11" font="font6" id="p1_t107" reading_order_no="104" segment_no="17" tag_type="text">Williams  et al. 28 retrospectively pooled safety</text>
<text top="600" left="318" width="239" height="9" font="font6" id="p1_t108" reading_order_no="105" segment_no="17" tag_type="text">data in 1538 patients with lymphoid malignancies</text>
<text top="612" left="318" width="239" height="9" font="font6" id="p1_t109" reading_order_no="106" segment_no="17" tag_type="text">treated with alemtuzumab in five single-arm trials and</text>
<text top="623" left="318" width="239" height="9" font="font6" id="p1_t110" reading_order_no="107" segment_no="17" tag_type="text">reported that 3.6% of patients experienced “symp-</text>
<text top="633" left="318" width="239" height="9" font="font6" id="p1_t111" reading_order_no="108" segment_no="17" tag_type="text">tomatic” CMV reactivation, CMV pneumonitis (0.8%),</text>
<text top="645" left="318" width="239" height="9" font="font6" id="p1_t112" reading_order_no="109" segment_no="17" tag_type="text">and CMV -related death (0.2%). Routine prospective<i>Pneumocystis</i></text>
<text top="656" left="318" width="239" height="9" font="font6" id="p1_t113" reading_order_no="110" segment_no="17" tag_type="text">screening of all patients for CMV reactivation was not<i>carinii</i> pneumonia (</text>
<text top="666" left="318" width="239" height="9" font="font6" id="p1_t114" reading_order_no="111" segment_no="17" tag_type="text">performed in those studies. Patients who developed</text>
<text top="678" left="318" width="239" height="9" font="font6" id="p1_t115" reading_order_no="112" segment_no="17" tag_type="text">CMV reactivation were usually treated with intrave-</text>
<text top="689" left="318" width="239" height="9" font="font6" id="p1_t116" reading_order_no="113" segment_no="17" tag_type="text">nous ganciclovir until evidence of viremia resolution.</text>
<text top="699" left="318" width="239" height="9" font="font6" id="p1_t117" reading_order_no="114" segment_no="17" tag_type="text">Ganciclovir therapy was highly effective for treating</text>
<text top="711" left="318" width="238" height="9" font="font6" id="p1_t118" reading_order_no="115" segment_no="17" tag_type="text">CMV reactivation, but because ganciclovir-induced</text>
<text top="722" left="318" width="239" height="9" font="font6" id="p1_t119" reading_order_no="116" segment_no="17" tag_type="text">neutropenia was common, myeloid growth factors<i>Single-Agent Alemtuzumab for Relapsed or Refrac-</i></text>
</page>
</pdf2xml>
